English
简体中文
Total: £ 56.28
Published Date: 2025-09-15 | Pages: 104 | Tables: 93 | Pharma & Healthcare
The global market for Biosimilar Drug was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product"s patent expires.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Biosimilar Drug by region & country, by Type, and by Application.
The Biosimilar Drug market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Drug.
Market Segmentation
By Company
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Biosimilar Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Biosimilar Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Biosimilar Drug Product Introduction
1.2 Global Biosimilar Drug Market Size Forecast
1.2.1 Global Biosimilar Drug Sales Value (2020-2031)
1.2.2 Global Biosimilar Drug Sales Volume (2020-2031)
1.2.3 Global Biosimilar Drug Sales Price (2020-2031)
1.3 Biosimilar Drug Market Trends & Drivers
1.3.1 Biosimilar Drug Industry Trends
1.3.2 Biosimilar Drug Market Drivers & Opportunity
1.3.3 Biosimilar Drug Market Challenges
1.3.4 Biosimilar Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biosimilar Drug Players Revenue Ranking (2024)
2.2 Global Biosimilar Drug Revenue by Company (2020-2025)
2.3 Global Biosimilar Drug Players Sales Volume Ranking (2024)
2.4 Global Biosimilar Drug Sales Volume by Company Players (2020-2025)
2.5 Global Biosimilar Drug Average Price by Company (2020-2025)
2.6 Key Manufacturers Biosimilar Drug Manufacturing Base and Headquarters
2.7 Key Manufacturers Biosimilar Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Biosimilar Drug
2.9 Biosimilar Drug Market Competitive Analysis
2.9.1 Biosimilar Drug Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Biosimilar Drug Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Drug as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Injection
3.1.2 Tablets
3.1.3 Other Types
3.2 Global Biosimilar Drug Sales Value by Type
3.2.1 Global Biosimilar Drug Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Biosimilar Drug Sales Value, by Type (2020-2031)
3.2.3 Global Biosimilar Drug Sales Value, by Type (%) (2020-2031)
3.3 Global Biosimilar Drug Sales Volume by Type
3.3.1 Global Biosimilar Drug Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Biosimilar Drug Sales Volume, by Type (2020-2031)
3.3.3 Global Biosimilar Drug Sales Volume, by Type (%) (2020-2031)
3.4 Global Biosimilar Drug Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ankylosing Spondylitis
4.1.2 Tumor
4.1.3 Rheumatoid Arthrtis
4.1.4 Cardiovascular
4.1.5 Other Application
4.2 Global Biosimilar Drug Sales Value by Application
4.2.1 Global Biosimilar Drug Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Biosimilar Drug Sales Value, by Application (2020-2031)
4.2.3 Global Biosimilar Drug Sales Value, by Application (%) (2020-2031)
4.3 Global Biosimilar Drug Sales Volume by Application
4.3.1 Global Biosimilar Drug Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Biosimilar Drug Sales Volume, by Application (2020-2031)
4.3.3 Global Biosimilar Drug Sales Volume, by Application (%) (2020-2031)
4.4 Global Biosimilar Drug Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Biosimilar Drug Sales Value by Region
5.1.1 Global Biosimilar Drug Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Biosimilar Drug Sales Value by Region (2020-2025)
5.1.3 Global Biosimilar Drug Sales Value by Region (2026-2031)
5.1.4 Global Biosimilar Drug Sales Value by Region (%), (2020-2031)
5.2 Global Biosimilar Drug Sales Volume by Region
5.2.1 Global Biosimilar Drug Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Biosimilar Drug Sales Volume by Region (2020-2025)
5.2.3 Global Biosimilar Drug Sales Volume by Region (2026-2031)
5.2.4 Global Biosimilar Drug Sales Volume by Region (%), (2020-2031)
5.3 Global Biosimilar Drug Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Biosimilar Drug Sales Value, 2020-2031
5.4.2 North America Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Biosimilar Drug Sales Value, 2020-2031
5.5.2 Europe Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Biosimilar Drug Sales Value, 2020-2031
5.6.2 Asia Pacific Biosimilar Drug Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Biosimilar Drug Sales Value, 2020-2031
5.7.2 South America Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Biosimilar Drug Sales Value, 2020-2031
5.8.2 Middle East & Africa Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biosimilar Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Biosimilar Drug Sales Value
6.2.1 Key Countries/Regions Biosimilar Drug Sales Value, 2020-2031
6.2.2 Key Countries/Regions Biosimilar Drug Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Biosimilar Drug Sales Value, 2020-2031
6.3.2 United States Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Biosimilar Drug Sales Value, 2020-2031
6.4.2 Europe Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Biosimilar Drug Sales Value, 2020-2031
6.5.2 China Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.5.3 China Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Biosimilar Drug Sales Value, 2020-2031
6.6.2 Japan Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Biosimilar Drug Sales Value, 2020-2031
6.7.2 South Korea Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Biosimilar Drug Sales Value, 2020-2031
6.8.2 Southeast Asia Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Biosimilar Drug Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Biosimilar Drug Sales Value, 2020-2031
6.9.2 India Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
6.9.3 India Biosimilar Drug Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 CP Guojian Pharma
7.1.1 CP Guojian Pharma Company Information
7.1.2 CP Guojian Pharma Introduction and Business Overview
7.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 CP Guojian Pharma Biosimilar Drug Product Offerings
7.1.5 CP Guojian Pharma Recent Development
7.2 Biotech Pharma
7.2.1 Biotech Pharma Company Information
7.2.2 Biotech Pharma Introduction and Business Overview
7.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Biotech Pharma Biosimilar Drug Product Offerings
7.2.5 Biotech Pharma Recent Development
7.3 Celgen Pharma
7.3.1 Celgen Pharma Company Information
7.3.2 Celgen Pharma Introduction and Business Overview
7.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Celgen Pharma Biosimilar Drug Product Offerings
7.3.5 Celgen Pharma Recent Development
7.4 Henlius
7.4.1 Henlius Company Information
7.4.2 Henlius Introduction and Business Overview
7.4.3 Henlius Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Henlius Biosimilar Drug Product Offerings
7.4.5 Henlius Recent Development
7.5 Amgen
7.5.1 Amgen Company Information
7.5.2 Amgen Introduction and Business Overview
7.5.3 Amgen Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Amgen Biosimilar Drug Product Offerings
7.5.5 Amgen Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Company Information
7.6.2 Eli Lilly Introduction and Business Overview
7.6.3 Eli Lilly Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Eli Lilly Biosimilar Drug Product Offerings
7.6.5 Eli Lilly Recent Development
7.7 Sandoz
7.7.1 Sandoz Company Information
7.7.2 Sandoz Introduction and Business Overview
7.7.3 Sandoz Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Sandoz Biosimilar Drug Product Offerings
7.7.5 Sandoz Recent Development
7.8 Changchun High Tech
7.8.1 Changchun High Tech Company Information
7.8.2 Changchun High Tech Introduction and Business Overview
7.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Changchun High Tech Biosimilar Drug Product Offerings
7.8.5 Changchun High Tech Recent Development
7.9 Innovent
7.9.1 Innovent Company Information
7.9.2 Innovent Introduction and Business Overview
7.9.3 Innovent Biosimilar Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Innovent Biosimilar Drug Product Offerings
7.9.5 Innovent Recent Development
8 Industry Chain Analysis
8.1 Biosimilar Drug Industrial Chain
8.2 Biosimilar Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biosimilar Drug Sales Model
8.5.2 Sales Channel
8.5.3 Biosimilar Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Biosimilar Drug Market Trends
Table 2. Biosimilar Drug Market Drivers & Opportunity
Table 3. Biosimilar Drug Market Challenges
Table 4. Biosimilar Drug Market Restraints
Table 5. Global Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 7. Global Biosimilar Drug Sales Volume by Company (2020-2025) & (K Dose)
Table 8. Global Biosimilar Drug Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Biosimilar Drug Price by Company (2020-2025) & (USD/Dose)
Table 10. Key Manufacturers Biosimilar Drug Manufacturing Base and Headquarters
Table 11. Key Manufacturers Biosimilar Drug Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Biosimilar Drug
Table 13. Global Biosimilar Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Drug as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Biosimilar Drug Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Biosimilar Drug Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Biosimilar Drug Sales Market Share in Value by Type (2020-2025)
Table 20. Global Biosimilar Drug Sales Market Share in Value by Type (2026-2031)
Table 21. Global Biosimilar Drug Sales Volume by Type: 2020 VS 2024 VS 2031 (K Dose)
Table 22. Global Biosimilar Drug Sales Volume by Type (2020-2025) & (K Dose)
Table 23. Global Biosimilar Drug Sales Volume by Type (2026-2031) & (K Dose)
Table 24. Global Biosimilar Drug Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Biosimilar Drug Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Biosimilar Drug Price by Type (2020-2025) & (USD/Dose)
Table 27. Global Biosimilar Drug Price by Type (2026-2031) & (USD/Dose)
Table 28. Global Biosimilar Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Biosimilar Drug Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Biosimilar Drug Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Biosimilar Drug Sales Market Share in Value by Application (2020-2025)
Table 32. Global Biosimilar Drug Sales Market Share in Value by Application (2026-2031)
Table 33. Global Biosimilar Drug Sales Volume by Application: 2020 VS 2024 VS 2031 (K Dose)
Table 34. Global Biosimilar Drug Sales Volume by Application (2020-2025) & (K Dose)
Table 35. Global Biosimilar Drug Sales Volume by Application (2026-2031) & (K Dose)
Table 36. Global Biosimilar Drug Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Biosimilar Drug Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Biosimilar Drug Price by Application (2020-2025) & (USD/Dose)
Table 39. Global Biosimilar Drug Price by Application (2026-2031) & (USD/Dose)
Table 40. Global Biosimilar Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Biosimilar Drug Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Biosimilar Drug Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Biosimilar Drug Sales Value by Region (2020-2025) & (%)
Table 44. Global Biosimilar Drug Sales Value by Region (2026-2031) & (%)
Table 45. Global Biosimilar Drug Sales Volume by Region (K Dose): 2020 VS 2024 VS 2031
Table 46. Global Biosimilar Drug Sales Volume by Region (2020-2025) & (K Dose)
Table 47. Global Biosimilar Drug Sales Volume by Region (2026-2031) & (K Dose)
Table 48. Global Biosimilar Drug Sales Volume by Region (2020-2025) & (%)
Table 49. Global Biosimilar Drug Sales Volume by Region (2026-2031) & (%)
Table 50. Global Biosimilar Drug Average Price by Region (2020-2025) & (USD/Dose)
Table 51. Global Biosimilar Drug Average Price by Region (2026-2031) & (USD/Dose)
Table 52. Key Countries/Regions Biosimilar Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Biosimilar Drug Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Biosimilar Drug Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Biosimilar Drug Sales Volume, (2020-2025) & (K Dose)
Table 56. Key Countries/Regions Biosimilar Drug Sales Volume, (2026-2031) & (K Dose)
Table 57. CP Guojian Pharma Company Information
Table 58. CP Guojian Pharma Introduction and Business Overview
Table 59. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 60. CP Guojian Pharma Biosimilar Drug Product Offerings
Table 61. CP Guojian Pharma Recent Development
Table 62. Biotech Pharma Company Information
Table 63. Biotech Pharma Introduction and Business Overview
Table 64. Biotech Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 65. Biotech Pharma Biosimilar Drug Product Offerings
Table 66. Biotech Pharma Recent Development
Table 67. Celgen Pharma Company Information
Table 68. Celgen Pharma Introduction and Business Overview
Table 69. Celgen Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 70. Celgen Pharma Biosimilar Drug Product Offerings
Table 71. Celgen Pharma Recent Development
Table 72. Henlius Company Information
Table 73. Henlius Introduction and Business Overview
Table 74. Henlius Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 75. Henlius Biosimilar Drug Product Offerings
Table 76. Henlius Recent Development
Table 77. Amgen Company Information
Table 78. Amgen Introduction and Business Overview
Table 79. Amgen Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 80. Amgen Biosimilar Drug Product Offerings
Table 81. Amgen Recent Development
Table 82. Eli Lilly Company Information
Table 83. Eli Lilly Introduction and Business Overview
Table 84. Eli Lilly Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 85. Eli Lilly Biosimilar Drug Product Offerings
Table 86. Eli Lilly Recent Development
Table 87. Sandoz Company Information
Table 88. Sandoz Introduction and Business Overview
Table 89. Sandoz Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. Sandoz Biosimilar Drug Product Offerings
Table 91. Sandoz Recent Development
Table 92. Changchun High Tech Company Information
Table 93. Changchun High Tech Introduction and Business Overview
Table 94. Changchun High Tech Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 95. Changchun High Tech Biosimilar Drug Product Offerings
Table 96. Changchun High Tech Recent Development
Table 97. Innovent Company Information
Table 98. Innovent Introduction and Business Overview
Table 99. Innovent Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 100. Innovent Biosimilar Drug Product Offerings
Table 101. Innovent Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Biosimilar Drug Downstream Customers
Table 105. Biosimilar Drug Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Drug Product Picture
Figure 2. Global Biosimilar Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Biosimilar Drug Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Biosimilar Drug Sales Volume (2020-2031) & (K Dose)
Figure 5. Global Biosimilar Drug Sales Price (2020-2031) & (USD/Dose)
Figure 6. Biosimilar Drug Report Years Considered
Figure 7. Global Biosimilar Drug Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Biosimilar Drug Players Sales Volume Ranking (2024) & (K Dose)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Biosimilar Drug Revenue in 2024
Figure 10. Biosimilar Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Injection Picture
Figure 12. Tablets Picture
Figure 13. Other Types Picture
Figure 14. Global Biosimilar Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Biosimilar Drug Sales Value Market Share by Type, 2024 & 2031
Figure 16. Global Biosimilar Drug Sales Volume by Type (2020 VS 2024 VS 2031) & (K Dose)
Figure 17. Global Biosimilar Drug Sales Volume Market Share by Type, 2024 & 2031
Figure 18. Global Biosimilar Drug Price by Type (2020-2031) & (USD/Dose)
Figure 19. Product Picture of Ankylosing Spondylitis
Figure 20. Product Picture of Tumor
Figure 21. Product Picture of Rheumatoid Arthrtis
Figure 22. Product Picture of Cardiovascular
Figure 23. Product Picture of Other Application
Figure 24. Global Biosimilar Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 25. Global Biosimilar Drug Sales Value Market Share by Application, 2024 & 2031
Figure 26. Global Biosimilar Drug Sales Volume by Application (2020 VS 2024 VS 2031) & (K Dose)
Figure 27. Global Biosimilar Drug Sales Volume Market Share by Application, 2024 & 2031
Figure 28. Global Biosimilar Drug Price by Application (2020-2031) & (USD/Dose)
Figure 29. North America Biosimilar Drug Sales Value (2020-2031) & (US$ Million)
Figure 30. North America Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
Figure 31. Europe Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 32. Europe Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
Figure 33. Asia Pacific Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Biosimilar Drug Sales Value by Region (%), 2024 VS 2031
Figure 35. South America Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 36. South America Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
Figure 37. Middle East & Africa Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 38. Middle East & Africa Biosimilar Drug Sales Value by Country (%), 2024 VS 2031
Figure 39. Key Countries/Regions Biosimilar Drug Sales Value (%), (2020-2031)
Figure 40. Key Countries/Regions Biosimilar Drug Sales Volume (%), (2020-2031)
Figure 41. United States Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 42. United States Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 43. United States Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 44. Europe Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 45. Europe Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 46. Europe Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 47. China Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 48. China Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 49. China Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 50. Japan Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 51. Japan Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 52. Japan Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 53. South Korea Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 54. South Korea Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 55. South Korea Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 56. Southeast Asia Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 57. Southeast Asia Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 58. Southeast Asia Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 59. India Biosimilar Drug Sales Value, (2020-2031) & (US$ Million)
Figure 60. India Biosimilar Drug Sales Value by Type (%), 2024 VS 2031
Figure 61. India Biosimilar Drug Sales Value by Application (%), 2024 VS 2031
Figure 62. Biosimilar Drug Industrial Chain
Figure 63. Biosimilar Drug Manufacturing Cost Structure
Figure 64. Channels of Distribution (Direct Sales, and Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
